COVID-19 has hit the pharmaceutical industry in the mergers and acquisitions, IP, and due diligence areas within the life science industry. The challenges arise as pharma companies cannot successfully perform their due diligence or close deals virtually, which creates a barrier to deals while there is an increase in the sellers market. However, professionals say that COVID-19 and the production of vaccines grabbed new eyes to the life science space - which is likely to increase investor interest and awareness to the role it plays around the world. Even so, they believe that drug pricing conversations may begin again due to the new healthcare policies of the presidential administration where the US will mainly focus on biopharma investors.
Within new trends emerging the pressure to meet growth expectations are placing added emphasis and challenges with internal pipeline and development challenges are now focused on M&A activities for Life Science Companies. It is imperative for today's organizations to develop robust M&A capabilities that address the challenges and opportunities of diversification; joint ventures, alliances, and licensing deals, and emerging markets.
Who Should Attend
Pharmaceutical, Biotechnology, and Medical Device professionals whose responsibilities include:
- Due Diligence
- Business Development
- Strategic Alliance/Alliance Management
- Mergers and Acquisitions
- Licensing
- BD&L
- Digital Partnerships
- Digital Investments
- Strategic Alliances/Partnerships Management
- Intellectual Property and Patent Counsel
- Search and Evaluation
- Portfolio Management
- General Counsel/Corporate Counsel
- Legal and Regulatory Compliance
- Legal / Intellectual Property
- Portfolio / Life Cycle Management
- Search and Evaluation
- External Innovation
- Clinical Operations
- Regulatory Affairs
- Compliance
- Scientific Assessment
- Transactions
Secondary Market
- Investment Banks
- Private Equity Firms
- Venture Capitalists
- Data Room Providers
- Due Diligence Consultants
- Law Firms
- Clinical Affairs and CRO Partners
- Regulatory Affairs and Compliance Specialists
Top 5 Reasons to Attend
- Maximize marketing efforts in order to increase facilities and IP due diligence
- Evaluating new insights on reimbursements, rules and regulations and how it impacts deal-making while mitigating risks
- Understanding the role and future of evolving trends such as digital therapeutics
- Refine your growth strategies by implementing M&A integration, diligence, and deal sourcing
- Evaluating the roadmap for integrating business development and the alliance management life-cycle
Networking Capabilities
- Virtual Matchmaking: Visit our virtual lobby and connect with fellow attendees using our platform's matchmaking technology. You can chat, video, and even make a list of the people you want to meet and the knowledge you're looking to gain through our bespoke 1:1 match-making services
- Roundtable Networking throughout the Summit will give you the chance to connect and meet in-depth your fellow attendees as well as our Sponsors and Speakers
- The platform we use allows us to make polls, QA, and chat during the sessions.
- Virtual Happy Hour: Grab a drink and bring it to your screen to cheers from afar while continuing to chat with and get to know your fellow conference participants.
Speakers
- Neil Berkley, Vice President, Head of Business Development, HALOZYME THERAPEUTICS
- Anu Daniel, Director, Due Diligence, SANOFI
- Somjeet Dey, Business Development and Alliance Management, OTSUKA
- Teresa Faria, Senior Director, Alliance Management, DAIICHI SANKYO
- Tayseer Ghazzouli, Senior Director, Head of Alliance Management & IC Support, JANSSEN
- Kenneth Jaconetty, Senior Director, IP Legal Lead For IP Transactions, ASTELLAS PHARMA
- Lizabeth Leveille, Vice President and Head, BD&L Boston & European Innovation Hubs, MERCK RESEARCH LABORATORIES
- Tushar Nuwal, Vice President, BD&L, Strategy & Alliance Management, POLYPID
- Oscar Riano, Sr. Manager, International Quality, MALLINCKRODT PHARMACEUTICALS
- Scott Simmons, Advisor, External Innovation – Due Diligence, ELI LILLY AND COMPANY
Please fill in your name and email to receive the Virtual Summit Agenda of this event.
Venue
The venue is not yet available for this event.
Follow this event to be informed when the venue is available and stay informed on other changes.
